New Upsher-Smith collaboration to grow its generics portfolio

MAPLE GROVE, Minn. — Upsher-Smith on Monday announced a new collaboration that expands its strategic partnerships and grows its generics portfolio. The company will collaborate with Bluepharma to develop and distribute a generic product in a category with U.S. sales more than $75 million, according to QuintilesIMS data for the 12 months ended July 2016. 

 

The agreement will see Bluepharma developing, manufacturing and supplying the product, and Upsher-Smith submitting the generic’s approval application to the Food and Drug Administration. Upsher-Smith will have exclusive rights to market and distribute the product under its label. The companies did not disclose financial terms. 

 

"For years, Upsher-Smith has been a trusted partner in the U.S. generics marketplace," said Rusty Field, President, Upsher-Smith. "Upsher-Smith's consistent growth and success within this market can be attributed to our ability to build solid strategic relationships with leading pharmaceutical companies, like Bluepharma who share in our commitment to delivering quality, high-value generic products to patients."